WO2022111497A1 - Application d'iode dans la préparation de médicaments pour la prévention et le traitement de maladies infectieuses des voies respiratoires - Google Patents

Application d'iode dans la préparation de médicaments pour la prévention et le traitement de maladies infectieuses des voies respiratoires Download PDF

Info

Publication number
WO2022111497A1
WO2022111497A1 PCT/CN2021/132640 CN2021132640W WO2022111497A1 WO 2022111497 A1 WO2022111497 A1 WO 2022111497A1 CN 2021132640 W CN2021132640 W CN 2021132640W WO 2022111497 A1 WO2022111497 A1 WO 2022111497A1
Authority
WO
WIPO (PCT)
Prior art keywords
iodine
infectious diseases
preventing
preparation
treating respiratory
Prior art date
Application number
PCT/CN2021/132640
Other languages
English (en)
Chinese (zh)
Inventor
金玉东
Original Assignee
金玉东
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 金玉东 filed Critical 金玉东
Publication of WO2022111497A1 publication Critical patent/WO2022111497A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the invention relates to the technical field of medicine, in particular to the application of iodine in the preparation of a medicine for preventing and treating respiratory infectious diseases.
  • the respiratory tract is composed of the nasal cavity, throat, trachea, bronchioles, respiratory bronchioles, alveolar ducts, and alveoli.
  • gas enters the alveoli from the nasal cavity, conducts gas exchange, and then exhales.
  • Pathogens attack from the nasal cavity to the alveoli, resulting in rhinitis (common cold), pharyngitis, tracheo-bronchitis, and pneumonia.
  • Common pathogens that cause respiratory tract infections include viruses, bacteria, mycoplasma, chlamydia, and fungi.
  • Viruses include respiratory syncytial virus, adenovirus, rhinovirus, coronavirus, influenza A virus, influenza B virus, SARS virus, avian influenza virus, new coronavirus, etc.
  • the new coronavirus (2019-nCoV) is a new strain of coronavirus. After infecting the human body, symptoms such as fever, cough, shortness of breath, and dyspnea can occur, which can lead to pneumonia, acute respiratory distress syndrome, renal failure, etc., and even death. There is currently no effective treatment for the new coronavirus.
  • Trial Version 4 the "Diagnosis and Treatment Program for Novel Coronavirus Infected Pneumonia (Trial Version 4) issued by the state, the use of interferon inhalation, lopinavir and ritonavir antiviral therapy was considered, but the efficacy was poor. Due to the lack of effective drugs for the treatment of new coronary pneumonia, drug development is particularly important.
  • Iodine is a strong oxidant, which can halogenate the proteins of pathogenic microorganisms such as viruses, bacteria, fungi, etc., destroy their protoplasmic protein active groups, and combine with the amino acids of proteins to denature them and lose their activity. It has a strong killing effect. Moreover, iodine has a very strong penetrating power to viruses, bacteria, etc., and has a rapid effect. If iodine is used to kill respiratory infectious viruses, including the new coronavirus, there will be surprises. However, after oral administration or injection of iodine, it is quickly reduced to iodine ions and loses biological activity, so it cannot reach the lungs with blood circulation to function.
  • iodine has not been clinically used in the treatment of respiratory infectious diseases.
  • respiratory virus infections such as new coronary pneumonia, bird flu, influenza A, influenza B and other severe infectious diseases, and the lack of effective therapeutic drugs, pose a great threat to human life safety.
  • Bacterial, mycoplasma, chlamydia, and fungal respiratory infections are particularly intractable due to drug resistance.
  • the key is to prepare iodine so that it has no stimulating effect on the mucous membrane of the respiratory tract. So far, this iodine preparation that can be inhaled by aerosol is still blank in the world.
  • Iodine is a disinfectant and corrosion drug, and there are currently three preparations: cidi iodine lozenges, iodine glycerin and iodine tincture.
  • Cidi iodine is composed of iodine molecules. Each tablet contains 1.5mg of iodine, a very small amount. It is taken orally. It is used to treat chronic pharyngitis, oral ulcers, chronic gingivitis, and periodontitis. It has been used clinically for decades. It has been proved that this dose of iodine taken orally is safe for the human body, and it is not irritating to the mucous membranes.
  • Iodine glycerin contains 10mg of iodine per milliliter. It is applied to the oral mucosa for the treatment of oral ulcers, gingivitis, and periodontitis. It has also been used for decades, indicating that it is safe.
  • the effective concentration of iodine to kill pathogenic microorganisms is 0.001%, which reduces the iodine content of iodine glycerol by 100 times, that is, 0.01%, which is 10 times the effective concentration.
  • Kill pathogenic microorganisms, and this low-concentration iodine solution has little irritation to mucous membranes, and can be safely inhaled through the respiratory tract to kill pathogens through atomization, filling the gap in the treatment of respiratory infectious diseases.
  • iodine tincture concentration 2%, formula: iodine, alcohol, potassium iodide, water; iodine glycerol concentration: 1%, formula: iodine, potassium iodide, glycerin, water; iodine water (now discarded) concentration: 1%, formula: iodine, potassium iodide, water, but the effective concentration of iodine to kill pathogenic microorganisms is 0.001%.
  • the concentration of iodine tincture is 2,000 times of the effective concentration, and the killing of pathogens is overwhelming.
  • the preparation of iodine into a disinfectant with a common concentration of 0.015% can not only effectively kill pathogens, but also greatly reduce irritation, which is a great innovation in the application of iodine disinfectant.
  • the present invention provides an application of iodine in the preparation of a medicament for preventing and treating respiratory infectious diseases.
  • the present invention proposes an application of iodine in the preparation of a medicament for preventing and treating respiratory infectious diseases.
  • the respiratory tract infection refers to respiratory tract infections caused by viruses, bacteria, mycoplasma, chlamydia, and fungi, including common cold, pharyngitis, tracheo-bronchitis, pneumonia, influenza A, influenza B, Avian flu and COVID-19.
  • the iodine is an element or molecule of iodine, and the element or molecule of iodine is made into a low-concentration iodine solution.
  • the invention also proposes an application of iodine in preparing low-concentration iodine disinfectant.
  • the concentration of the low-concentration iodine disinfectant is lower than 0.5%.
  • the present invention also provides a method for preparing a small particle size iodine-containing aerosol, which comprises atomizing or granulating it.
  • the atomizing includes:
  • Step S11 mixing elemental iodine and purified water
  • Step S12 preparing the iodine element and purified water into an iodine solution
  • Step S13 passing the iodine solution through an atomizing device to form a small particle size iodine-containing aerosol
  • Step S14 inhaling the atomized iodine-containing aerosol into the alveoli
  • Step S15 The iodine in the iodine-containing aerosol kills pathogenic microorganisms.
  • the common concentration of the iodine solution is 0.015%.
  • the granulating comprises:
  • Step S21 mixing iodine element and oily liquid
  • Step S22 preparing the iodine element and the oily liquid into an iodine solution
  • Step S23 atomizing the iodine solution by an electronic atomizer to form a small particle size iodine-containing aerosol;
  • Step S24 inhaling the atomized iodine-containing aerosol into the alveoli
  • Step S25 the iodine in the iodine-containing aerosol kills pathogenic microorganisms.
  • the step 21 is carried out according to the ratio of mixing 20 mg of iodine element per 1 ml of oily liquid.
  • iodine can efficiently kill various pathogens, and it was mainly used in the sterilization of skin and oral mucosa in the human body before.
  • iodine is prepared into a low-concentration iodine solution as an atomizing agent, which is atomized into an iodine-containing aerosol and inhaled into the respiratory tract, which can not only ensure the killing of pathogenic microorganisms, but also minimize the stimulating effect on the mucous membrane, so that iodine can be applied to respiratory tract infections. Treatment of sexually transmitted diseases becomes a reality.
  • iodine quickly and efficiently kills pathogenic microorganisms that multiply abnormally in the respiratory tract, and becomes a special medicine for respiratory infectious diseases.
  • the successfully prepared low-concentration iodine aerosol is a special drug. After inhalation, it can easily kill various viruses and quickly control influenza A and B. Influenza, bird flu, new coronary pneumonia and other serious infectious diseases.
  • low-concentration iodine aerosol inhalation is used to inhale the alveoli, and active iodine vigorously kills the new coronavirus, so that mild cases can be quickly recovered, and severe and critical cases can be quickly out of danger, saving countless lives. Even if the new coronavirus mutates greatly in the future, or other respiratory infectious diseases appear, it can be solved by inhalation of low-concentration iodine aerosol to avoid panic. Low-concentration iodine aerosol inhalation also provides an efficient and simple treatment method for other pathogens such as common viruses and bacteria in the respiratory tract, and can also solve the problem of drug resistance. It is a subversive revolution in the treatment of respiratory infectious diseases. In the face of any respiratory infectious disease in the future, human beings can be calm, because they have a powerful weapon to efficiently eliminate pathogens.
  • the prepared low-concentration iodine disinfectant is less irritating, safer and has a wider application range.
  • Fig. 1 is the flow chart of a kind of method of preparing low particle size iodine-containing aerosol of the preferred embodiment of the present invention
  • FIG. 2 is a flow chart of a method for preparing a low particle size iodine-containing aerosol according to another preferred embodiment of the present invention.
  • the invention proposes the application of iodine in the preparation of medicines for preventing and treating respiratory infectious diseases.
  • iodine is dissolved in pure water and glycerin, and two types of iodine solution atomizers are respectively prepared, which are atomized into iodine-containing aerosols by the atomizer and inhaled into the respiratory tract to kill pathogens quickly and efficiently. It is the only specific drug for the treatment of respiratory viral infections, and provides more effective and convenient therapeutic drugs for respiratory bacteria, mycoplasma, fungi and other infections.
  • the respiratory tract infection refers to respiratory tract infections caused by viruses, bacteria, mycoplasma, chlamydia, fungi, etc., including common cold, pharyngitis, tracheo-bronchitis, pneumonia, influenza A, influenza B , bird flu, new coronary pneumonia, and other respiratory infectious diseases in the future.
  • the iodine is an element or molecule of iodine, and the element or molecule of iodine is made into a low-concentration iodine solution.
  • the invention also proposes the application of iodine in the preparation of low-concentration disinfectant.
  • the concentration of the low-concentration iodine disinfectant is lower than 0.5%, and the common concentration is 0.015%.
  • the present invention also provides a method for preparing a small particle size iodine-containing aerosol, which comprises atomizing or granulating it.
  • the atomization includes:
  • the atomizing includes:
  • Step S11 iodine elemental substance and pure water are mixed
  • Step S12 iodine elemental substance and pure water are prepared into iodine solution
  • Step S13 the iodine solution is formed into a small particle size iodine-containing aerosol by atomizing device;
  • Step S14 the iodine-containing aerosol after the atomization is inhaled into the alveoli
  • Step S15 the iodine in the iodine-containing aerosol kills pathogenic microorganisms.
  • the concentration of the iodine solution is 0.015%.
  • iodine is dissolved in pure water, and it is prepared into a 0.015% low-concentration iodine solution, which is atomized and inhaled three times a day. Compression nebulizer is selected, the fog particles are fine and the median particle size (MMD) is about 2.2 ⁇ m to ensure that a certain proportion of aerosol can reach the alveoli.
  • MMD median particle size
  • the iodine is prepared into a very low concentration solution of 0.015%, and then atomized into an aerosol, which greatly reduces the density of iodine, greatly reduces the irritation of iodine, and can safely enter the respiratory tract.
  • the granulation includes:
  • the granulating comprises:
  • Step S21 mixing elemental iodine and glycerol
  • Step S22 preparing an iodine solution from elemental iodine and glycerol
  • Step S23 atomizing the iodine solution by an electronic atomizer to form a low particle size iodine-containing aerosol
  • Step S24 inhaling the atomized iodine-containing aerosol into the alveoli
  • Step S25 The iodine in the iodine-containing aerosol kills pathogenic microorganisms.
  • the step 21 is performed according to the ratio of mixing 20 mg of iodine element per 1 ml of glycerol.
  • the diameter of the particles entering the alveoli needs to be less than 2.25 ⁇ m. Since the compressed atomization inhalation cannot fully meet this requirement, some iodine cannot enter the alveoli.
  • an electronic atomizer is used to turn the glycerol-iodine solution into a smoke-like aerosol with a particle size of less than 2.25 ⁇ m, which can smoothly enter the alveoli and greatly improve the therapeutic effect of pulmonary infection.
  • iodine and glycerin are mixed in a ratio of 20mg: 1ml to prepare a glycerol-iodine solution, which is transformed into a smoke-like iodine-containing aerosol by an electronic atomizer.
  • a glycerol-iodine solution Three times a day. 2ml of glycerol-iodine solution can suck 400 large mouths.
  • This method can ensure that most of the iodine-containing aerosol enters the alveoli, allowing iodine to fully exert its killing effect.
  • the preparation of iodine into aerosol can greatly reduce the density of iodine, greatly reduce the irritation, and make it a reality that iodine molecules enter the respiratory tract to kill pathogens.
  • the small particle size iodine-containing aerosol can reach the alveoli and directly kill the pathogens in the alveoli, so that the critical and severe cases of pulmonary infection can be quickly out of
  • Cidi iodine lozenges are composed of a single iodine molecule. Dissolve two tablets in 20ml of sterile water to prepare a 0.015% solution, and inhale into the respiratory tract three times a day. It has been used in the treatment of common cold, influenza A, influenza B, bronchial Inflammation, pneumonia, etc., the effect is rapid.
  • Symptoms fever, cough, sore throat, shortness of breath, etc.
  • Treatment method stop other drugs, give 0.015% iodine solution atomization inhalation, 20ml each time, 3 times a day. Pneumonia patients were inhaled with glycerol-iodine solution, 20 large mouthfuls each time, three times a day.
  • iodine can effectively kill various pathogens. It was mainly used in the sterilization of skin and oral mucosa in the human body.
  • the present invention prepares iodine into a low-concentration atomizer, which is atomized into aerosol for inhalation, which can not only ensure the effective killing of pathogenic microorganisms, but also minimize the irritation to the respiratory mucosa, making the application of iodine in the treatment of respiratory infectious diseases a reality.
  • the prepared low-concentration iodine aerosol can easily kill various viruses after inhalation, and quickly control influenza A, influenza B, avian influenza, and new crowns.
  • Severe infectious diseases such as pneumonia.
  • low-concentration iodine solution and glycerol-iodine solution are used to atomize and inhale the alveoli, and active iodine vigorously kills the new coronavirus in the alveoli, so that mild cases can be quickly recovered, and severe and critical cases can be quickly removed from the danger of life, saving countless lives.
  • active iodine vigorously kills the new coronavirus in the alveoli, so that mild cases can be quickly recovered, and severe and critical cases can be quickly removed from the danger of life, saving countless lives.
  • the new coronavirus mutates greatly in the future, or other respiratory infectious diseases appear, they can be used to solve the problem and avoid panic.
  • Inhalation of iodine-containing aerosols also provides an efficient and simple treatment method for other pathogens such as common viruses and bacteria in the respiratory tract, and can also solve the problem of drug resistance. It is a subversive revolution in the treatment of respiratory infectious diseases.
  • the prepared low-concentration iodine disinfectant is less irritating and safer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une application d'iode dans la préparation de médicaments destinés à la prévention et/ou au traitement de maladies infectieuses des voies respiratoires. L'iode est dissous séparément dans de l'eau pure et un solvant huileux pour préparer deux types de solutions d'iode à faible concentration, de manière à obtenir deux types d'agents de pulvérisation de solution d'iode, qui sont nébulisés en un aérosol contenant de l'iode par un nébuliseur et ensuite inhalés dans des voies respiratoires.
PCT/CN2021/132640 2020-11-27 2021-11-24 Application d'iode dans la préparation de médicaments pour la prévention et le traitement de maladies infectieuses des voies respiratoires WO2022111497A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011358617.2A CN112791097A (zh) 2020-11-27 2020-11-27 碘在制备预防、治疗呼吸道感染性疾病的药物中的应用以及制备低粒径含碘气溶胶的方法
CN202011358617.2 2020-11-27

Publications (1)

Publication Number Publication Date
WO2022111497A1 true WO2022111497A1 (fr) 2022-06-02

Family

ID=75806327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/132640 WO2022111497A1 (fr) 2020-11-27 2021-11-24 Application d'iode dans la préparation de médicaments pour la prévention et le traitement de maladies infectieuses des voies respiratoires

Country Status (2)

Country Link
CN (1) CN112791097A (fr)
WO (1) WO2022111497A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112791097A (zh) * 2020-11-27 2021-05-14 金玉东 碘在制备预防、治疗呼吸道感染性疾病的药物中的应用以及制备低粒径含碘气溶胶的方法
CN113952366A (zh) * 2021-09-07 2022-01-21 中兆科生物科技(深圳)有限公司 一种防治新冠病毒的配置方法及应用
CN113875782A (zh) * 2021-10-14 2022-01-04 中兆科生物科技(深圳)有限公司 一种灭杀新冠病毒外用喷雾剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260281A1 (en) * 2004-05-19 2005-11-24 Mathew Thyparambil C Upper respiratory tract virus infection preventive therapy
CN111437288A (zh) * 2020-05-20 2020-07-24 山东沙多普生物科技有限公司 一种雾化分子碘消毒制剂及其应用
CN111956660A (zh) * 2020-03-17 2020-11-20 姚舜 用含碘消毒液雾化防治病毒性呼吸道疾病的方法
CN112791097A (zh) * 2020-11-27 2021-05-14 金玉东 碘在制备预防、治疗呼吸道感染性疾病的药物中的应用以及制备低粒径含碘气溶胶的方法
CN113244262A (zh) * 2020-02-07 2021-08-13 北京天衡军威医药技术开发有限公司 一种用于预防及治疗呼吸道感染性疾病的吸入粉雾制剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260281A1 (en) * 2004-05-19 2005-11-24 Mathew Thyparambil C Upper respiratory tract virus infection preventive therapy
CN113244262A (zh) * 2020-02-07 2021-08-13 北京天衡军威医药技术开发有限公司 一种用于预防及治疗呼吸道感染性疾病的吸入粉雾制剂
CN111956660A (zh) * 2020-03-17 2020-11-20 姚舜 用含碘消毒液雾化防治病毒性呼吸道疾病的方法
CN111437288A (zh) * 2020-05-20 2020-07-24 山东沙多普生物科技有限公司 一种雾化分子碘消毒制剂及其应用
CN112791097A (zh) * 2020-11-27 2021-05-14 金玉东 碘在制备预防、治疗呼吸道感染性疾病的药物中的应用以及制备低粒径含碘气溶胶的方法

Also Published As

Publication number Publication date
CN112791097A (zh) 2021-05-14

Similar Documents

Publication Publication Date Title
WO2022111497A1 (fr) Application d'iode dans la préparation de médicaments pour la prévention et le traitement de maladies infectieuses des voies respiratoires
KR100910888B1 (ko) 에어로졸화 이송을 위한 적절한 토브라마이싱의 조성물
US5897872A (en) Iodine-containing nasal moisturizing saline solution
KR20120002981A (ko) 호흡기 감염 치료를 위한 약제 제형 및 방법
US8709496B2 (en) Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract
JPH05501263A (ja) グルタチオンのエーロゾル製剤
EP2594283B1 (fr) Préparation aérosol à base d'aprotinine pour traiter les infections respiratoires virales
JP2007507423A (ja) 病原体感染の危険を低減する方法
CN111956660A (zh) 用含碘消毒液雾化防治病毒性呼吸道疾病的方法
US20200268656A1 (en) Nebulized Ethanol for Internal Disinfecting and Improvement
CN115671291A (zh) 一种基于g型褐藻寡糖的雾化剂、雾化剂浓缩液及其制备方法和应用
CN103893165A (zh) 用于治疗呼吸系统疾病的雾化吸入剂
JPH02279625A (ja) アレルゲンにより誘発された鼻の反応を治療するための吸入ループ利尿剤
CN105287846A (zh) 山海丹鱼金注射液在雾化吸入、喷瓶气雾、直肠给药的应用及方法
US20130216574A1 (en) Kit providing multiple unmet therapeutic effects
Barry et al. Nebuliser therapy in childhood
US6362225B1 (en) Target therapies for treating common viral infections
US20060210482A1 (en) Chemical composition and method for cold and sinus relief
RU2353376C1 (ru) Способ лечения и профилактики бронхопневмонии у телят и поросят
JP6975473B2 (ja) 鼻詰まりを治療／予防するためのカルボン酸
WO2022063320A1 (fr) Composition pour inhiber un virus respiratoire et méthode de prévention et de traitement de virus respiratoire
US11213530B2 (en) Gallium in the treatment of coronavirus disease
EP4125814A1 (fr) Composés iodé pour le traitement de pathogènes respiratoires
CN112472669A (zh) 一种基于红辣椒提取物和肝素预防流感的鼻腔喷雾剂及其制备方法
TW201016215A (en) Compositions and uses of antiviral active pharmaceutical agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21896998

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 20.10.2023)